SCHEMBL7734451

SCHEMBL7734451

CCCCn1ccc(-c2ccccc2O)c(N)c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 3/20 0.48
ALDH1A1 P00352 5/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GRM2 Q14416 3/20 0.38
EPHB4 P54760 1/20 0.38
TYR P14679 1/20 0.38
CNR2 P34972 2/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
TNF P01375 1/20 0.36
CNR1 P21554 1/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7736232 0.82 TLR8 (0.49) TLR8ALDH1A1NPSR1GRM2CNR2
SCHEMBL8154381 0.81 ALDH1A1 (0.55) TLR8ALDH1A1NPSR1TDP1L3MBTL1
SCHEMBL7726225 0.80 NPC1 (0.40) TLR8ALDH1A1NPSR1TDP1GRM2
SCHEMBL9453852 0.75 ALDH1A1 (0.54) ALDH1A1NPSR1TDP1L3MBTL1GRM2
SCHEMBL8171070 0.72 ALDH1A1 (0.42) TLR8ALDH1A1NPSR1TDP1L3MBTL1
SCHEMBL16088173 0.70 ALDH1A1 (0.49) TLR8ALDH1A1NPSR1GRM2TYR
SCHEMBL8160720 0.70 TNF (0.41) TLR8ALDH1A1NPSR1TDP1L3MBTL1
SCHEMBL27636352 0.69 ALDH1A1 (0.48) TLR8ALDH1A1NPSR1TYRCNR2
SCHEMBL31041845 0.69 ALDH1A1 (0.48) TLR8ALDH1A1NPSR1TYRCNR2
SCHEMBL1039006 0.69 ALDH1A1 (0.55) ALDH1A1NPSR1TDP1L3MBTL1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK TLR8 3948/4885ALDH1A1 716/4885NPSR1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.